Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols

What Was Tested

Researchers studied hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin) in this randomized controlled trial publication.

Who Took Part

The study group was 35 women.

The age groups tagged for this paper are adults, women only.

This two-arm randomized open-label study included 35 HH women (aged 25-36 yr) attending their Center.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

The women were allocated by chance, so the hCG (human chorionic gonadotropin) group and the comparison group should start out alike.

Nothing was hidden in this open-label hCG (human chorionic gonadotropin) study: the women and staff both knew the treatment.

Ovulation was induced by a single administration of hCG on the day after the last hMG-HP or r-hFSH/r-hLH.

What Was Measured

The subject headings attached to it are Anovulation, Chi-Square Distribution, Chorionic Gonadotropin, Drug Combinations, Estradiol, Follicle Stimulating Hormone and Infertility, Female.

What This Means in Plain Language

The paper is a randomized and open-label study of hCG (human chorionic gonadotropin) and HMG (Human Menopausal Gonadotropin) in 35 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (Journal of endocrinological investigation), a journal based in Italy.

More context: the hCG (human chorionic gonadotropin) compound page and the HMG (Human Menopausal Gonadotropin) compound page, all human trials.